Palisade Bio, Inc. $PALI Shares Acquired by Orbimed Advisors LLC

Orbimed Advisors LLC grew its position in shares of Palisade Bio, Inc. (NASDAQ:PALI) by 24.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,333,000 shares of the company’s stock after purchasing an additional 461,580 shares during the quarter. Orbimed Advisors LLC owned approximately 1.34% of Palisade Bio worth $4,083,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Commodore Capital LP purchased a new position in Palisade Bio in the fourth quarter valued at $26,896,000. Artia Global Partners LP acquired a new position in shares of Palisade Bio in the fourth quarter worth about $4,682,000. Creek Drive Management Group LLC purchased a new stake in shares of Palisade Bio during the 4th quarter worth about $723,000. Perceptive Advisors LLC purchased a new stake in shares of Palisade Bio during the 4th quarter worth about $28,318,000. Finally, BIT Capital GmbH acquired a new stake in shares of Palisade Bio during the 4th quarter valued at about $717,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Price Performance

PALI stock opened at $1.95 on Monday. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.86. The firm has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $1.89. The stock has a market capitalization of $338.48 million, a P/E ratio of -1.93 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts expect that Palisade Bio, Inc. will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a research note on Tuesday, June 30th. Wolfe Research initiated coverage on Palisade Bio in a research report on Thursday, April 9th. They set an “outperform” rating and a $7.00 price target on the stock. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Finally, Oppenheimer started coverage on Palisade Bio in a research note on Thursday. They set an “outperform” rating and a $8.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Palisade Bio presently has an average rating of “Buy” and an average target price of $9.00.

Insider Buying and Selling at Palisade Bio

In other news, CEO John David Finley sold 146,798 shares of Palisade Bio stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total value of $303,871.86. Following the sale, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at $450,338.85. The trade was a 40.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert Jr. Baltera purchased 30,000 shares of the stock in a transaction dated Tuesday, July 7th. The stock was purchased at an average cost of $2.03 per share, for a total transaction of $60,900.00. Following the completion of the purchase, the director directly owned 416,904 shares of the company’s stock, valued at approximately $846,315.12. The trade was a 7.75% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 125,000 shares of company stock valued at $250,100 over the last quarter. 0.07% of the stock is currently owned by insiders.

Palisade Bio Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.